Skip to main content
. 2018 Oct 14;7(11):5457–5469. doi: 10.1002/cam4.1808

Figure 4.

Figure 4

Percentage of dose intensity for each treatment cohort by specific time points where the starting point is the full starting dose and subsequent time points reflect the mean percent dose of the starting dose. Das: dasatinib; Pon: ponatinib; Nil: nilotinib. Ponatinib cohort has terminated this study between 18 and 20 mo of therapy due to severe cardiovascular complications. Eventually, dose intensity went down to 0% at 24 mo